First digital endpoints to land on drug labels this year, DiME CEO predicts
Digital Medicine Society CEO Goldsack said approvals based on digital endpoints are on the way
The use of digital endpoints in clinical trials is expanding rapidly, and they will soon be included on drug labels, Jennifer Goldsack, CEO of the Digital Medicine Society, predicted.
“I would be shocked if we didn’t have a label this year” with a digital endpoint, Goldsack said in an interview with The BioCentury Show. She added that an approval this year based on a digital endpoint is possible. ...